US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by AAVantgarde
AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
October 04, 2026
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde to Showcase Clinical Progress in Usher 1B and Stargardt Disease at EURetina 2026
September 16, 2026
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer
September 01, 2026
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde Announces Participation of Founder and CSO, Prof. Alberto Auricchio at the 32nd Annual Meeting of the Japanese Society for Gene and Cell Therapy
July 23, 2026
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study
April 23, 2026
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde announces completion of recruitment in STELLA natural history study
April 21, 2026
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde appoints Philip Lao as Senior Vice President of Business Development
April 01, 2026
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
January 15, 2026
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 08, 2026
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
November 03, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
October 07, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
October 02, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
September 05, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025
August 28, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
August 12, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
July 15, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
May 12, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer
April 28, 2025
From
AAVantgarde
Via
GlobeNewswire
